Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BIIB
BIIB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BIIB News
Italy Investigates Biogen for Market Dominance Abuse
3d ago
seekingalpha
Biotech Sector Regulatory Approvals and Collaborations
May 22 2026
NASDAQ.COM
Biogen Shares Plunge 6.4% After CELIA Trial Misses Endpoint
May 22 2026
PRnewswire
Biogen and Denali Halt Development of Parkinson's Drug BIIB122
May 22 2026
seekingalpha
Biogen and Denali Discontinue BIIB122 for Parkinson's Disease
May 22 2026
NASDAQ.COM
Biogen and Denali Halt Development of Parkinson's Drug BIIB122
May 22 2026
NASDAQ.COM
Biogen and Denali Halt Parkinson's Drug Development
May 21 2026
stocktwits
Pomerantz LLP Investigates Biogen for Securities Fraud
May 21 2026
PRnewswire
Biogen and Denali Discontinue BIIB122 Development in Parkinson's Disease
May 21 2026
Globenewswire
Biogen and Denali Discontinue BIIB122 Development in Parkinson's Disease
May 21 2026
Newsfilter
Biogen Shares Drop 6.4% After CELIA Trial Data Misses Primary Endpoint
May 18 2026
PRnewswire
Biogen Shares Drop 6.4% After CELIA Trial Data Misses Key Endpoint
May 15 2026
PRnewswire
Biogen Shares Drop 6.4% After CELIA Trial Data Misses Endpoint
May 15 2026
Newsfilter
Investment Opportunities in Biogen and Novo Nordisk: A Comparative Analysis
May 14 2026
Fool
Biogen Advances Alzheimer's Drug to Late-Stage Testing Despite Mixed Results
May 14 2026
CNBC
Bitcoin-Linked Stocks Rise as Starbucks Gets Upgrade
May 14 2026
CNBC
Show More News
